What's new?

Added 18 hours ago Drug news

Phase III DAPA-HF trial of Farxiga positive for treatment of heart failure.-AstraZeneca

AstraZeneca announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite...

Added 18 hours ago Drug news

FDA approves Xenleta to treat community-acquired bacterial pneumonia - Nabriva Therapeutics

Nabriva Therapeutics plc announced that the FDA has approved Nabriva’s new drug applications for the oral and intravenous (IV) formulations...

Added 18 hours ago Drug news

Myovant Sciences completes ptient recruitment for phase III SPIRIT 2 study evaluating relugolix combination therapy in women with endometriosis.

Myovant Sciences announced that it has completed patient recruitment for its SPIRIT 2 study, the first of two Phase III...

Added 18 hours ago Drug news

Winlevi filed with FDA for acne.- Cassiopea

Cassiopea has submitted a New Drug Application (NDA) to the FDA seeking marketing approval for Winlevi (clascoterone cream 1%) for...

Added 18 hours ago Drug news

EPOCH 2 Phase III study of HTX 011 in pain control published in Hernia journal.- Heron Therapeutics

Heron Therapeutics announced that the results from EPOCH 2, a Phase III study of the investigational agent HTX 011 (bupivacaine...